Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoing Elective IntubationNCT07480304
To Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laeyngoscopy and Intubation in Patients Undergoing Elective Intubation
A study testing Nebulization of dexmedetomedine in group D and Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored. in people with Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoing Elective Intubation, run by Dow University of Health Sciences at 1 site in Pakistan.
Trial summary
Laryngoscopy and intubation are painful stimuli ,that results in adverse physiological outcomes,like tachycrdia ,hypertension,arrythmiaa,pulmonary edema. The main objective of study is to blunt the autonomic response of laryngoscopy and intubation. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoing Elective Intubation
- What is being tested?
- Nebulization of dexmedetomedine in group D and Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Dec 2025to Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18-65 years ASAI-III Both genders Patients undergoing elective intubation
Who cannot join
- Patients with renal hepatic or neurological disease Bleeding diathesis Mallampatti III-IV Previous histoey of difficult intubation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: To Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoung Elective Intubation
Laryngoscopy and intubation are painful stimuli ,that results in adverse physiological outcomes,like tachycrdia ,hypertension,arrythmiaa,pulmonary edema.
The main objective of study is to blunt the autonomic response of laryngoscopy and intubation.
Read more
Title of the study :To evaluate the effect of dexmedetimedine nebulization upon blunting autonomic response of laryngoscopy and intubation in patients undergoing elective intubation.
It is randomized control trial,sample size was calculated by using openEpi sample size calculator By using SBPafter 1 min of laeyngoscopy in decmedetomedine versus group were 113.2+_14.503and 125.92+_15.263 respectively,power 95 percent and confidence 95 percent ,The required sample size for the study is 72( 36 ) in each group.
After taking informed consent patients are randomly divided into two groups via opaque sealed envelop technique.Half of envelops will be labelled as letter D ,and half will be labelled as letter C .Patients in group D will be nebulized with dexmedetomedine with dose of 1ug/kg made total volume of 5 ml with normal saline.While group C will be nebulized with 5 ml of 0.9 percent normal saline 30 min prior to elective intubation.Hemodynamic parmmeters heart rate ,systolic bp,diastolic bp,MAP will be noted at baseline and 0,1,5,10 min after inrubation
- Being tested
- Nebulization of dexmedetomedine in group D, Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nebulization of dexmedetomedine in group DDrug
After taking informed consent ,patients are divided into 2 groups by using opaque sealed envelop technique ,half envelope were labelled with letter D ,half were labelled with letter patients in group D will be nebulized wirh dexmedetimedine wuth dose of 1ug/kgwith made total volune of 5ml by mixing with norml saline 30 min prior to intubation
Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored.Drug
Groyp c will be nebulized with normal saline 30 min prior to intubation,hemodynamic parameters heart rate,systolic bp ,diastolic bp,MAP, will be monitored at baseline,0,1,5,10 min after intubation.
| Study group | Role | What they receive |
|---|---|---|
| Dexmedetomedine nebulization in group D | Experimental | Dexmedetomedine nebulization done with a dose of1ug /kg 30min prioor to induction of general anaesthesia Receives: Drug: Nebulization of dexmedetomedine in group D |
| Normal saline nebulization in group C | Active comparator | Normal saline nebulization done 30min prior to induction of general anaesthesia,hemdynamic parameters heart rate,systolic bp,diastolic bp,MAP,will be noted at baseline,0,1,5,10 min after intubation Receives: Drug: Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored. |
What is being measured
The primary outcome is the main question the study is designed to answer.
heart rate will be recorded at 0,1,5,10 min after laryngoscopy and intubation
Measured: Heart rate will be monitired at base line,0min,1min,5min,10min after intervention
SBP,DBP,MAP. measurement will be required at o ,1,5,10 min after laryngoscopy and intubation.
Measured: SBP,DBP,MAP, will be recorded at 0,1,5,10 min after laryngoscopy and intubation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2026
- Study start1 Dec 2025
- Primary completionApr 2026 (estimated)
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoing Elective IntubationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dow University of Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hafiza Javeria Jawed, Dow University of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07480304
- Sponsor's protocol ID
- IRB4343/DUHS/Approval/2025/479
- Status last verified
- Mar 2026
- First submitted
- 1 Mar 2026
- Last updated
- 18 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoung Elective Intubation
- ClinicalTrials.gov ID
- NCT07480304
- Acronym / sponsor ID
- IRB4343/DUHS/Approval/2025/479
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Dow University of Health SciencesUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- Apr 2026 (estimated)
- First posted
- 18 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Laryngoscopy and intubation are painful stimuli ,that results in adverse physiological outcomes,like tachycrdia ,hypertension,arrythmiaa,pulmonary edema.
The main objective of study is to blunt the autonomic response of laryngoscopy and intubation.
Title of the study :To evaluate the effect of dexmedetimedine nebulization upon blunting autonomic response of laryngoscopy and intubation in patients undergoing elective intubation.
It is randomized control trial,sample size was calculated by using openEpi sample size calculator By using SBPafter 1 min of laeyngoscopy in decmedetomedine versus group were 113.2+_14.503and 125.92+_15.263 respectively,power 95 percent and confidence 95 percent ,The required sample size for the study is 72( 36 ) in each group.
After taking informed consent patients are randomly divided into two groups via opaque sealed envelop technique.Half of envelops will be labelled as letter D ,and half will be labelled as letter C .Patients in group D will be nebulized with dexmedetomedine with dose of 1ug/kg made total volume of 5 ml with normal saline.While group C will be nebulized with 5 ml of 0.9 percent normal saline 30 min prior to elective intubation.Hemodynamic parmmeters heart rate ,systolic bp,diastolic bp,MAP will be noted at baseline and 0,1,5,10 min after inrubation
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dexmedetomedine nebulization in group D | Experimental | Drug: Nebulization of dexmedetomedine in group DDexmedetomedine nebulization done with a dose of1ug /kg 30min prioor to induction of general anaesthesia |
| Normal saline nebulization in group C | Active comparator | Drug: Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored.Normal saline nebulization done 30min prior to induction of general anaesthesia,hemdynamic parameters heart rate,systolic bp,diastolic bp,MAP,will be noted at baseline,0,1,5,10 min after intubation |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Age 18-65 years ASAI-III Both genders Patients undergoing elective intubation
Key exclusion criteria (1 listed)
- Patients with renal hepatic or neurological disease Bleeding diathesis Mallampatti III-IV Previous histoey of difficult intubation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nebulization of dexmedetomedine in group DAfter taking informed consent ,patients are divided into 2 groups by using opaque sealed envelop technique ,half envelope were labelled with letter D ,half were labelled with letter patients in group D will be nebulized wirh dexmedetimedine wuth dose of 1ug/kgwith made total volune of 5ml by mixing with norml saline 30 min prior to intubation | Drug | Dexmedetomedine nebulization in group D |
| Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored.Groyp c will be nebulized with normal saline 30 min prior to intubation,hemodynamic parameters heart rate,systolic bp ,diastolic bp,MAP, will be monitored at baseline,0,1,5,10 min after intubation. | Drug | Normal saline nebulization in group C |
Primary outcome
heart rate will be recorded at 0,1,5,10 min after laryngoscopy and intubation
Time frame: Heart rate will be monitired at base line,0min,1min,5min,10min after intervention
SBP,DBP,MAP. measurement will be required at o ,1,5,10 min after laryngoscopy and intubation.
Time frame: SBP,DBP,MAP, will be recorded at 0,1,5,10 min after laryngoscopy and intubation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nebulization of dexmedetomedine in group D and Nebulizition with normal saline in group C,after taking informed consent patients in group cwill be nebulized with 5 ml of normal saline 30 min prior to elective intubation ,HR,SBP,DBP,MAP monitored. in people with Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoing Elective Intubation, run by Dow University of Health Sciences at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
heart rate will be recorded at 0,1,5,10 min after laryngoscopy and intubation (time frame: Heart rate will be monitired at base line,0min,1min,5min,10min after intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.